Cargando…

Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers

BACKGROUND: The function of collagen triple helix repeat containing 1 (CTHRC1) as an oncogene has been reported in a growing number of publications. Bioinformatics methods represent a beneficial approach to examine the mechanism and function of the CTHRC1 gene in the disease process of cancers from...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Dazhao, Wei, Cheng, Zhang, Xiaoyang, Li, Shenghui, Liang, Hao, Zheng, Xingyu, Jiang, Shulong, Han, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549344/
https://www.ncbi.nlm.nih.gov/pubmed/34702252
http://dx.doi.org/10.1186/s12935-021-02266-3
_version_ 1784590764371607552
author Peng, Dazhao
Wei, Cheng
Zhang, Xiaoyang
Li, Shenghui
Liang, Hao
Zheng, Xingyu
Jiang, Shulong
Han, Lei
author_facet Peng, Dazhao
Wei, Cheng
Zhang, Xiaoyang
Li, Shenghui
Liang, Hao
Zheng, Xingyu
Jiang, Shulong
Han, Lei
author_sort Peng, Dazhao
collection PubMed
description BACKGROUND: The function of collagen triple helix repeat containing 1 (CTHRC1) as an oncogene has been reported in a growing number of publications. Bioinformatics methods represent a beneficial approach to examine the mechanism and function of the CTHRC1 gene in the disease process of cancers from a pan-cancer perspective. METHODS: In this study, using the online databases UCSC, NCBI, HPA, TIMER2, Oncomine, GEPIA, UALCAN, cBioPortal, COSMIC, MEXPRESS, STRING, CCLE, LinkedOmics, GTEx, TCGA, CGGA, and SangerBox, we focused on the relationship between CTHRC1 and tumorigenesis, progression, methylation, immunity, and prognosis. qPCR was used to detect CTHRC1 expression in glioma tissues and cell lines. RESULTS: The pan-cancer analysis showed that CTHRC1 was overexpressed in most tumors, and a significant correlation was observed between CTHRC1 expression and the prognosis of patients with cancer. CTHRC1 genetic alterations occur in diverse tumors and are associated with tumor progression. Levels of CTHRC1 promoter methylation were decreased in most cancer tissues compared with normal tissues. In addition, CTHRC1 coordinated the activity of ICP genes through diverse signal transduction pathways, was also associated with immune cell infiltration and the tumor microenvironment, and potentially represented a promising immunotherapy target. We identified CTHRC1-related genes across cancers using the GEPIA2 tool. The single-gene GO analysis of CTHRC1 across cancers showed that it was involved in some signaling pathways and biological processes, such as the Wnt signaling pathway, cell migration, and positive regulation of protein binding. The expression and function of CTHRC1 were also further verified in glioma tissues and cell lines. CONCLUSIONS: CTHRC1 is overexpressed in various cancer types and functions as an important oncogene that may promote tumorigenesis and development through different mechanisms. CTHRC1 may represent an important therapeutic target for human cancers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-02266-3.
format Online
Article
Text
id pubmed-8549344
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85493442021-10-27 Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers Peng, Dazhao Wei, Cheng Zhang, Xiaoyang Li, Shenghui Liang, Hao Zheng, Xingyu Jiang, Shulong Han, Lei Cancer Cell Int Primary Research BACKGROUND: The function of collagen triple helix repeat containing 1 (CTHRC1) as an oncogene has been reported in a growing number of publications. Bioinformatics methods represent a beneficial approach to examine the mechanism and function of the CTHRC1 gene in the disease process of cancers from a pan-cancer perspective. METHODS: In this study, using the online databases UCSC, NCBI, HPA, TIMER2, Oncomine, GEPIA, UALCAN, cBioPortal, COSMIC, MEXPRESS, STRING, CCLE, LinkedOmics, GTEx, TCGA, CGGA, and SangerBox, we focused on the relationship between CTHRC1 and tumorigenesis, progression, methylation, immunity, and prognosis. qPCR was used to detect CTHRC1 expression in glioma tissues and cell lines. RESULTS: The pan-cancer analysis showed that CTHRC1 was overexpressed in most tumors, and a significant correlation was observed between CTHRC1 expression and the prognosis of patients with cancer. CTHRC1 genetic alterations occur in diverse tumors and are associated with tumor progression. Levels of CTHRC1 promoter methylation were decreased in most cancer tissues compared with normal tissues. In addition, CTHRC1 coordinated the activity of ICP genes through diverse signal transduction pathways, was also associated with immune cell infiltration and the tumor microenvironment, and potentially represented a promising immunotherapy target. We identified CTHRC1-related genes across cancers using the GEPIA2 tool. The single-gene GO analysis of CTHRC1 across cancers showed that it was involved in some signaling pathways and biological processes, such as the Wnt signaling pathway, cell migration, and positive regulation of protein binding. The expression and function of CTHRC1 were also further verified in glioma tissues and cell lines. CONCLUSIONS: CTHRC1 is overexpressed in various cancer types and functions as an important oncogene that may promote tumorigenesis and development through different mechanisms. CTHRC1 may represent an important therapeutic target for human cancers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-02266-3. BioMed Central 2021-10-26 /pmc/articles/PMC8549344/ /pubmed/34702252 http://dx.doi.org/10.1186/s12935-021-02266-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Primary Research
Peng, Dazhao
Wei, Cheng
Zhang, Xiaoyang
Li, Shenghui
Liang, Hao
Zheng, Xingyu
Jiang, Shulong
Han, Lei
Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers
title Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers
title_full Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers
title_fullStr Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers
title_full_unstemmed Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers
title_short Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers
title_sort pan-cancer analysis combined with experiments predicts cthrc1 as a therapeutic target for human cancers
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549344/
https://www.ncbi.nlm.nih.gov/pubmed/34702252
http://dx.doi.org/10.1186/s12935-021-02266-3
work_keys_str_mv AT pengdazhao pancanceranalysiscombinedwithexperimentspredictscthrc1asatherapeutictargetforhumancancers
AT weicheng pancanceranalysiscombinedwithexperimentspredictscthrc1asatherapeutictargetforhumancancers
AT zhangxiaoyang pancanceranalysiscombinedwithexperimentspredictscthrc1asatherapeutictargetforhumancancers
AT lishenghui pancanceranalysiscombinedwithexperimentspredictscthrc1asatherapeutictargetforhumancancers
AT lianghao pancanceranalysiscombinedwithexperimentspredictscthrc1asatherapeutictargetforhumancancers
AT zhengxingyu pancanceranalysiscombinedwithexperimentspredictscthrc1asatherapeutictargetforhumancancers
AT jiangshulong pancanceranalysiscombinedwithexperimentspredictscthrc1asatherapeutictargetforhumancancers
AT hanlei pancanceranalysiscombinedwithexperimentspredictscthrc1asatherapeutictargetforhumancancers